Mohsen Sadatsafavi

MISCELLANEOUS

• Twenty-year trends in excess costs of chronic obstructive pulmonary disease
• A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk.
• Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada
• Validation of the 4C prediction models to inform care for patients with COVID-19: final steps towards clinical application

METHODOLOGY

• Marginal versus conditional odds ratios when updating risk prediction models
• Model-Based ROC Curve: Examining the Effect of Case Mix and Model Calibration on the ROC Plot
• Uncertainty and the value of information in risk prediction modeling
• Non-parametric inference on calibration of predicted risks
• Closed-Form Solution of the Unit Normal Loss Integral in Two-Dimensions
• A Threshold-Free Summary Index for Quantifying the Capacity of Covariates to Yield Efficient Treatment Rules
• The association between rate and severity of exacerbations in chronic obstructive pulmonary disease: an application of a joint frailty-logistic model
• Relative Impact Characteristic (RIC) curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers
• Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcome
• A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy
• Incorporating external evidence in trial-based cost-effectiveness analysis: the use of resampling methods
• The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis – a case study of pharmacotherapies for moderate to severe COPD
• Two-level resampling as a novel method for calculation of the expected value of sample information in economic trials
• A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework
• Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information

ASTHMA

• International variation in severe exacerbation rates in patients with severe asthma
• Cost-effectiveness of budesonide-formoterol vs inhaled epinephrine in US adults with mild asthma
• Development of a conceptual model of childhood asthma to inform asthma prevention policies
• Long-term natural history of severe asthma exacerbations and their impact on the disease course
• Association between asthma control trajectories in preschoolers and long-term asthma control
• 16-year trends in asthma hospital admissions in Canada
• The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
• Trends in oral corticosteroids use in severe asthma: a 14-year population-based study
• The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada
• International severe asthma registry (ISAR): protocol for a global registry
• Does the occurrence of a severe asthma exacerbation change the rate of subsequent events?
• The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK
• Cost-effectiveness of Implementing Objective Diagnostic Verification of Asthma in the United States
• Stability of asthma symptom control in a longitudinal study of mild–moderate asthmatics
• Complementary and alternative asthma treatments and their association with asthma control: a population-based study
• History of Asthma in Patients with Chronic Obstructive Pulmonary Disease: A Comparative Study of Economic Burden.
• The preventable burden of productivity loss due to suboptimal asthma control: a population-based study
• The impact of comorbidities on productivity loss in asthma patients
• Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study
• A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma
• Asthma is not associated with the need for surgery in Crohn’s disease when controlling for smoking status: a population-based cohort study.
• Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
• The importance of measuring asthma control in emerging economies.
• The projected economic and health burden of sub-optimal asthma control in Canada
• Has asthma medication use caught up with the evidence? A 12-year population-based study of trends
• Predictors of inappropriate usage of reliever medications in asthma: a 12-year population-based study
• Dispensation of long-acting β agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study
• Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: a population-based study
• Influences of Socioeconomic Status on Costs of Asthma Under Universal Health Coverage
• Excess medical costs in patients with asthma and the role of comorbidity
• Ten-year trends in direct costs of asthma: a population-based study
• Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: A simulation study
• The natural history of severe asthma and influences of early risk factors: a population-based cohort study
• Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma
• The impact of inappropriate use of short acting beta agonists in asthma
• One-year outcomes of inhaled controller therapies added to systemic corticosteroids after asthma-related hospital discharge
• Post-hospital syndrome in adults with asthma: a case-crossover study
• Costs and health outcomes associated with primary versus secondary care after an asthma-related hospitalization, a population-based study
• Less chaos in the prognosis of asthma-chronic obstructive lung disease overlap.
• The projected economic and health burden of uncontrolled asthma in the United States
• The economic burden of multimorbidity in severe asthma patients: a 20-year population-based study
• Asthma control and productivity loss in those with work-related asthma: a population-based study

COPD

• QRISK3 underestimates the risk of cardiovascular events in patients with COPD
• A Cost-Effectiveness Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
• The hidden and unchecked judgement calls when using exacerbation history for managing COPD
• Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
• A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
• External validation of lung function predictions in real-world cohorts of COPD
• ACCEPT 2·0: Recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT)
• Generalizability of risk stratification algorithms for exacerbations in COPD
• Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study
• The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
• Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
• Predicting Severe COPD Exacerbations: Developing a Population Surveillance Approach with Administrative Data
• Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study
• Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline
• Looking at the COPD spectrum through “PRISm”
• Individualized prediction of lung-function decline in chronic obstructive pulmonary disease
• The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis.
• The diagnostic performance of patient symptoms in screening for COPD
• Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis
• COPD: undefeated!
• The global economic burden of asthma and chronic obstructive pulmonary disease
• Future impact of various interventions on the burden of COPD in Canada: a dynamic population model.
• Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
• The Projected Epidemic Of COPD Hospitalizations Over the Next 15 Years: A Population Based Perspective
• Excess economic burden of comorbidities in COPD: a 15-year population-based study
• Heterogeneity’s ruses: the neglected role of between-individual variability in longitudinal studies of COPD exacerbations
• A systematic review of health economics simulation models of chronic obstructive pulmonary disease
• Predicting severe COPD exacerbations: A population surveillance approach with administrative data
• An individualized prediction model for long-term lung function trajectory and risk of COPD in the general population
• Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada

IMPACT

• IMplementing Predictive Analytics towards efficient COPD Treatments (IMPACT): protocol for a stepped-wedge cluster randomized impact study.

METHODS

• Developing an online infrastructure to enhance model accessibility and validation: The Peer Models Network

PRECHEALTHASTHMA

• The economics of precision health: preventing air pollution-induced exacerbation in asthma

CPM

• Moving beyond AUC: decision curve analysis for quantifying net benefit of risk prediction models
• Validation and Utility Testing of Clinical Prediction Models: Time to Change the Approach
• Testing Clinical Prediction Models—Reply

EPIC

• Development and validation of the Evaluation Platform In COPD (EPIC): a population-based outcomes model of COPD for Canada
• Cost-Effectiveness of Case Detection Strategies for the Early Detection of COPD

ACCEPT

• The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study